1. European Medicines Agency. EMEA/CHMP/BMWP/42832/2005 Rev1: Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: non-clinical and clinical issues; 18 December 2014. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2015/01/WC500180219.pdf (accessed 18 Aug 2015).
2. Food and Drug Administration. Biosimilars: Questions and Answers Regarding Implementation of the Biologics Price Competition and Innovation Act of 2009: Guidance for Industry; April 2015. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM444661.pdf (accessed 18 Aug 2015).
3. World Health Organization. Guidelines on evaluation of similar biotherapeutic products (SBPs). 2009. http://www.who.int/biologicals/areas/biological_therapeutics/BIOTHERAPEUTICS_FOR_WEB_22APRIL2010.pdf (accessed 3 Sep 2015).
4. Health Canada. GUIDANCE FOR SPONSORS: Information and Submission Requirements for Subsequent Entry Biologics (SEBs). 2010. http://www.hc-sc.gc.ca/dhp-mps/alt_formats/pdf/brgtherap/applic-demande/guides/seb-pbu/seb-pbu-2010-eng.pdf (accessed 7 Oct 2015).
5. Pharmaceuticals and Medical Devices Agency, Japan. Guidelines for the quality, safety and efficacy assurance of follow-on biologics. 2009. http://www.nihs.go.jp/dbcb/TEXT/yakusyokushinsahatu-0304007.pdf (Japanese language only).